BackGalmed Pharmaceuticals Overview

Galmed Pharmaceuticals Other Current Assets

Latest other current assets for GLMD: $130K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$125000.00
2.46% YoYΔ $3000.00 vs prior year quarter

Peer average

Loading

Galmed Pharmaceuticals Other Current Assets History

Loading

Galmed Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Galmed Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Galmed Pharmaceuticals (GLMD) FAQ

The latest other current assets for GLMD is $130K as of March 2026. That compares with $120K in the prior-year period — up 2.5% year over year. Investors often review this figure alongside Galmed Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, GLMD's other current assets moved from $120K to $130K — a 2.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Galmed Pharmaceuticals's operating scale or balance-sheet position.

A other current assets figure of $130K for GLMD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GLMD's other current assets ($130K), review year-over-year change from $120K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Galmed Pharmaceuticals's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.